Join us on Friday 25th November for an afternoon event:
Special Keynote with Professor David Nutt (UK) and other researchers at Monash University Neuromedicines Discovery Centre.
“Next Generation Medicines for Better Mental Health”
12 – 5pm, Friday 25th November 2022
Lecture Theatre 3, Monash Institute of Pharmaceutical Sciences,
Monash University, 381 Royal Parade, Parkville 3052
- 12.00 Arrival & light lunch, coffee and tea
- 12.50 Welcome & Introduction Prof. Arthur Christopoulos, Monash University
- 1.00 Keynote Lecture – Psychedelic-Assisted Therapies: History, Neuroscience and Myths Prof. David Nutt, Imperial College, UK
- 2.00 Break
- 2.15 Introduction to the Neuromedicines Discovery Centre and its research mission Prof. Chris Langmead, Monash University
- 2.30 The potential of psychedelics for treating anorexia nervosa Dr Claire Foldi, Monash University
- 2.45 MDMA assisted psychotherapy to treat PTSD & AUD: insights from preclinical models Dr Leigh Walker, Florey Institute
- 3.00 The PSICONNECT trial Mr Devon Stoliker, Monash University
- 3.15 Break
- 3.30 Ketamine for treatment-resistant depression Prof. Chris Davey, University of Melbourne
- 3.45 Healthcare economics of psychedelic medicines Prof. Cathy Mihalopoulos, Monash University
- 4.00 Community attitudes to using psychedelic drugs in treating mental health disorders Dr Melissa Hatty, Monash University
- 4.15 Panel Q&A session TBC
- 4.45 Wrap up & close Prof. Arthur Christopoulos, Monash University
Prof David Nutt (UK)
BA, MB BChir, MRCP, MA, DM, MRC Psych, FRCPsych, FMedSci, FRCP, FSB
Renowned researcher, policy advisor and author, Professor David Nutt, is currently Head of Neuropsychopharmacology at Imperial College London and the Chair of Drug Science.
Under the leadership of Professor Nutt, the Psychedelic Research Group at Imperial College is one of the world’s foremost psychedelic research laboratories, publishing landmark research on psychedelic therapies and neuroimaging studies of the psychedelic state.
Professor Nutt has also held many leadership positions in both UK and European academic, scientific and clinical organisations, including presidencies of: the European Brain Council, the British Neuroscience Association, the British Association of Psychopharmacology, the European College of Neuropsychopharmacology.
He was previously Chair of the UK Advisory Council on the Misuse of Drugs.
Prof Arthur Christopoulos
BPharm, PH.D, FAA, FAHMS
Arthur Christopoulos is Professor of Analytical Pharmacology, Dean of the Faculty of Pharmacy & Pharmaceutical Sciences, and Director of the Neuromedicines Discovery Centre, Monash University, Parkville, Australia. Prior to his appointment as Dean, he was a Senior Principal Research Fellow of the NHMRC. His work focuses on novel paradigms of drug action at G protein-coupled receptors, the largest drug-target class for current medicines, and has been applied to fundamental and translational studies encompassing neurological and psychiatric disorders, cardiovascular disease, obesity, diabetes and chronic pain.
Professor Christopoulos has over 340 publications, including in leading journals such as Nature, Science and Cell. He has also been the recipient of multiple major national and international awards. Since 2014-present, Clarivate Analytics have named him a Highly Cited Researcher in Pharmacology and Toxicology, and in 2021 also named him a Highly Cited Researcher in Biology & Biochemistry. In 2017, he was elected a Fellow of the Australian Academy of Health and Medical Sciences and in 2021 was elected a Fellow of the Australian Academy of Science.